Skip to content

Comparison of excimer light and narrow band ultraviolet B phototherapy post vitiligo surgery

Comparison of efficacy of excimer light versus narrow band ultraviolet B phototherapy post autologous non cultured melanocyte transfer in stable vitiligo patients: a prospective interventional pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/054136
Enrollment
40
Registered
2023-06-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: excimer light: Based on MED, dose will be calculated for each patient and will be given over surgical site at 2,4,8 and 12 weeks post surgery Control Intervention1: narrow band Ultravio

Sponsors

self no sponsor
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All consecutive patients of age between 12 and 70 years, with two or more comparable patches of stable vitiligo,(stable for 6 months) attending Dermatology OPD in a tertiary care hospital

Exclusion criteria

Exclusion criteria: 1. Consent Denial and un-cooperative patients 2. Patients outside age criteria 3. Contraindication to surgical procedure 4. History of hypertrophic scarring and â?? or keloid 5. Vitiligo patches over palms, soles, and mucosae 6. Allergic â?? phototoxic reaction (lidocaine, tegaderm, suture strips and sunlight) 7. Use of medications known to cause photosensitivity and â?? or phototoxicity, other photosensitive and photoaggravated skin disorders that would impair evaluation of repigmentation. 8. Personal or family history of skin cancer or photosensitivity and â?? or photo toxicity disorders 9. Pregnancy

Design outcomes

Primary

MeasureTime frame
to be studied -efficacy of excimer light vs narrow band UV B -Extent of repigmentation (%) (ii) Dermoscopic repigmentation patternsTimepoint: 0wk,2wk,4wk,8wk,12wk

Secondary

MeasureTime frame
(i) Patient factors influencing pigmentation (ii) Cumulative dose (iii) Adverse effectsTimepoint: 0wk,2wk,4wk,8wk,12wk

Countries

India

Contacts

Public ContactDr Jeeva John

Institute of naval medicine, INHS Asvini, Colaba,Mumbai

reetuagarwal@gmail.com9987129923

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026